Trial Profile
A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination versus insulin glargine on top of metformin in type 2 diabetic patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Sanofi
- 09 Jun 2016 Results published in the Diabetes Care
- 09 Jun 2015 Results of a post-hoc analysis to determine whether the risk of symptomatic hypoglycaemia is affected by reductions in HbA1c presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 03 Jun 2015 Additional results will be presented at the 75th Scientific Sessions of the American Diabetes Association (ADA), according to a Zealand Pharma media release.